voprecotestВопросы экономикиVoprosy Ekonomiki0042-8736Voprosy Ekonomiki, NP10.32609/0042-8736-2021-6-139-156voprecotest-3300Research ArticleЭКОНОМИКА ИННОВАЦИЙECONOMICS OF INNOVATIONИнновационный профиль предприятий российской фармацевтической отрасли: «пациент скорее жив, чем мертв»Innovative profile of the Russian pharmaceutical industryhttps://orcid.org/0000-0003-3589-8386ПодшиваловаМ. В.PodshivalovaM. V.

Подшивалова Мария Владимировна, д. э. н., доцент, проф. кафедры «Финансовые технологии» ЮУрГУ

Челябинск

Chelyabinsk

podshivalovamv@susu.ruhttps://orcid.org/0000-0002-3605-7995ПылаеваИ. С.PylaevaI S.

Пылаева Ирина Сергеевна, аспирант кафедры «Финансовые технологии» ЮУрГУ

Челябинск

Chelyabinsk

irenpylaeva74@gmail.comhttps://orcid.org/0000-0001-5067-1302АлмршедС. К.AlmrshedS. K.

Алмршед Саттар Кадим, преподаватель кафедры менеджмента Университета Аль-Мутанна

Эс-Самава

Samawah

sattarchelyabinsk@gmail.comЮжно-Уральский государственный университетРоссияSouth-Ural State UniversityRussian FederationУниверситет Аль-МутаннаИракAl-Muthanna UniversityIraq20210706202106139156Copyright © Voprosy Ekonomiki, NP, 20212021Voprosy Ekonomiki, NPVoprosy Ekonomiki, NPhttps://www.vopreco.ru/jour/about/submissions#copyrightNoticehttps://www.vopreco.ru/jour/article/view/3300

В статье исследуется специфика инновационной активности отечественных предприятий — производителей лекарств, которая в условиях пандемии коронавируса стала значимой для национальной безопасности. Были использованы панельные данные: из общего числа предприятий отрасли (1816) сформирована выборка из 345 инновационно активных предприятий с рядами данных длиной 20 лет. Выборка диверсифицирована по масштабамдеятельности предприятий: микропредприятия, малые, средние и крупные. Эти типы предприятий сравниваются как по абсолютным показателям (размер вложений в нематериальные активы, возраст), так и относительным (частота инвестиций в инновации, коэффициент автономии, рентабельность продаж и активов, доля нематериальных активов в выручке и активах). Проанализированы предприятия, не вошедшие в выборку, чтобы выявить эффективность внедрения инноваций в отрасли. Создан инновационный профиль предприятий отрасли в разрезе масштабов деятельности, а также сделан вывод о специфике инновационной активности предприятий отечественной фармацевтической отрасли, в которой, как и в глобальной фармацевтике, крупные предприятия лидируют в разработке и внедрении инноваций. Российским крупным компаниям также свойственно использовать микропредприятия для реализации рискованных проектов. В целом в России заложены основы для перехода к новой модели инновационного развития фармацевтической отрасли, основанной на кооперации крупного и малого бизнеса.

InnoThe article examines the specifics of innovative activity of Russian drug manufacturers, which in the context of a COVID-19 pandemic become a matter of national security. The research is based on panel data: out of a total of 1,816 enterprises in the industry, a sample of 345 innovatively active enterprises is formed with a time series of data 20 years long. The sample is diversified by the scale of enterprise activity into 4 groups: micro enterprises, small, medium, and large enterprises. These types of enterprises are compared both in absolute terms — size of investments in intangible assets, age, and in relative ones — frequency of investments in innovations, coefficient of autonomy, profitability of sales and assets, share of intangible assets in revenue and assets. The analysis was supplemented by enterprises not included in the sample to identify the effectiveness of innovation in the industry. The result is the innovative profile of industrial enterprises in the context of the scale of their activities. The conclusion is drawn about the specifics of the domestic pharmaceutical industry innovation activity, which generally coincides with the established distribution of roles in the global pharmaceutical industry, when large enterprises are leaders in the innovations development and implementation. Russian large companies also tend to use micro enterprises to implement risky projects. The authors conclude that in Russia, the foundations have been formed for transition to a new model of pharmaceutical industry innovative development. This model is based on cooperation of small and large businesses.

инновационная активностьпромышленные предприятияпроизводство лекарстввысокотехнологичная отрасльмалое предпринимательствонематериальные активыинновационный профильinnovation activityindustrial enterprisesdrug productionhigh-tech industrysmall businessintangible assetsinnovation profileСтатья выполнена при поддержке Правительства РФ (Постановление №211 от 16.03.2013 г.), соглашение № 02.A03.21.0011The article was supported by the Government of the Russian Federation (Resolution No. 211 of 16.03.2013), Agreement No. 02. A03. 21. 0011ReferencesMcKinsey (2018). Инновации в России — неисчерпаемый источник роста. Центр по развитию инноваций McKinsey.McKinsey (2018). Innovations in Russia: A sustainable source of growth. McKinsey Innovation Practice. (In Russian).Брижанина Т. А. (2014). Малый бизнес: суть, преимущества, развитие // Вестник Челябинского государственного университета. № 2. С. 32—37.Brizhanina T. A. (2014). Small business: Еssence, advantages, development. Chelyabinsk State University Bulletin, No. 2, pp. 32—37. (In Russian).Варфоломеев Д. (2019.) Инвестиции в агропромышленный комплекс: этапы развития, тенденции, особенности // Экономика и жизнь. 30 мая.Varfolomeev D. (2019). Investments in the agro-industrial complex: Stages of development, trends, features. Ekonomika i Zhizn, May 30. (In Russian).Василенок В. Л., Сафронова Ж. С., Бразевич Д. С. (2018). Малое предпринимательство как фактор развития инновационной экономики // Научный журнал НИУ ИТМО. Серия: Экономика и экологический менеджмент. № 1. С. 98—104.Vasilenok V. L., Safronova Z. S., Brazevich D. S. (2018). Small business as a factorof development of innovative economy. Scientific Journal NRU ITMO. Series: Economics and Environmental Management, No. 1, pp. 98—104. (In Russian).] https://doi.org/10.17586/2310-1172-2018-11-1-98-104Гохберг Л. М., Дитковский К. А., Кузнецова И. А. и др. (2019). Индикаторы инновационной деятельности: 2019: стат. сб. М.: НИУ ВШЭ.Gokhberg L. M., Ditkovskiy K. A., Kuznetsova I. A. et al. (2019). Indicators of innovation in the Russian Federation: 2019: Data book. Moscow: HSE. (In Russian).Евсеева И. Н., Буев В. В., Рачковская И. А., Чепуренко А. Ю. (1998). Взаимодействие малых предприятий с крупным производством на региональном уровне. М.: ИСАРП.Evseeva I. N., Buev V. V., Rachkovskaya I. A., Chepurenko A. Y. (1998). Interaction of small enterprises with large-scale production at the regional level. Moscow: ISARP. (In Russian).Елисеев А. Н. (2009). Тенденции развития малого предпринимательства в России // Вестник Тамбовского университета. Серия: Гуманитарные науки. № 9. С. 56—61.Eliseev A. N. (2009). Trends in the development of small business in Russia. Tambov University Review. Series: Humanities, No. 9, pp. 56—61. (In Russian).Жолобов П. С. (2017). Использование опыта институтов развития стран БРИКС в деятельности Группы Внешэкономбанка // Экономика: вчера, сегодня, завтра. Т. 7, № 1А. С. 249—258.Zholobov P. S. (2017). Using the experience of development institutions of the BRICS countries in the activities of Vnesheconombank Group. Economics: Yesterday, Today and Tomorrow, Vol. 7, No. 1A, pp. 249—258. (In Russian).Заболоцкая В. В. (2012). Теоретико-концептуальные подходы к исследованию сущности малого предпринимательства // Экономика: теория и практика. № 1. С. 53—59.Zabolotskaya V. V. (2012). Theoretical and conceptual approaches to the study of the essence of small business. Ekonomika: Teoriya i Praktika, No. 1, pp. 53—59. (In Russian).Мамедьяров З. А. (2018). Инновационное развитие глобальной фармацевтической отрасли. Дисс. ... канд. экон. наук. М.: ИМЭМО РАН.Mamedyarov Z. A. (2018). Innovative development of the global pharmaceutical industry: Thesis. Moscow: IMEMO RAN. (In Russian).Подшивалова М. (2014). Качество социально-экономических институтов, формирующих среду развития малого бизнеса // Вопросы экономики. № 6. С. 97—111.Podshivalova M. (2014). Analysis of the quality of basic social and economic institutions that form environment of small business development. Voprosy Еkonomiki, No. 6, pp. 97—111. (In Russian). https://doi.org/10.32609/0042-8736-2014-6-97-111Симонова Е. В. (2010). Формы интеграции малого, среднего и крупного бизнеса: проблемы развития // Научные записки ОрелГИЭТ. № 2. С. 335—340.Simonova E. V. (2010). Forms of integration of small, medium and large businesses: Development problems. Scientific Journal of Orel SIET, No. 2, pp. 335—340. (In Russian).Сырцова Л. В. (2011). Опыт организации и оценка эффективности малого бизнеса в общественном питании // Транспортное дело России. № 1. С. 75—76.Syrtsova L. V. (2011). Experience of organizing and evaluating the effectiveness of small business in public catering. Transport Вusiness of Russia, No. 1, pp. 75—76. (In Russian).Хейфец Б. (2013). Деофшоризация экономики: мировой опыт и российская специфика // Вопросы экономики. № 7. С. 29—48.Kheyfets B. (2013). Deoffshorization of economy: International experience and Russian specifics. Voprosy Ekonomiki, No. 7, pp. 29—48. (In Russian). https://doi.org/10.32609/0042-8736-2013-7-29-48Шумпетер Й. А. (2008). Теория экономического развития. Капитализм, социализм и демократия. М.: Эксмо.Schumpeter J. A. (2008). The theory of economic development. Capitalism, socialism and democracy. Moscow: Eksmo. (In Russian).Adams R., Bessant J., Phelps R. (2006). Innovation management measurement: A review. International Journal of Management Review, Vol. 8, No. 1, pp. 21—47. https:// doi.org/10.1111/j.1468-2370.2006.00119.xAdams R., Bessant J., Phelps R. (2006). Innovation management measurement: A review. International Journal of Management Review, Vol. 8, No. 1, pp. 21—47. https:// doi.org/10.1111/j.1468-2370.2006.00119.xAdizes I. (1979). Organizational passages-diagnosing and treating lifecycle problems of organizations. Organizational Dynamics, Vol. 8, No. 1, pp. 3—25. https://doi.org/10.1016/0090-2616(79)90001-9Adizes I. (1979). Organizational passages-diagnosing and treating lifecycle problems of organizations. Organizational Dynamics, Vol. 8, No. 1, pp. 3—25. https://doi.org/10.1016/0090-2616(79)90001-9Anthony J. H., Ramesh K. (1992). Association between accounting performance measures and stock prices: A test of the life-cycle hypothesis. Journal of Accounting and Economics, Vol. 15, No. 2—3, pp. 203—227. https://doi.org/10.1016/0165-4101(92)90018-WAnthony J. H., Ramesh K. (1992). Association between accounting performance measures and stock prices: A test of the life-cycle hypothesis. Journal of Accounting and Economics, Vol. 15, No. 2—3, pp. 203—227. https://doi.org/10.1016/0165-4101(92)90018-WArdito L., Petruzzelli A., Savino T. (2018). Maturity of knowledge inputs and innovation value: The moderating effect of firm age and size. Journal of Business Research, No. 86, pp. 190—201. https://doi.org/10.1016/j.jbusres.2018.02.009Ardito L., Petruzzelli A., Savino T. (2018). Maturity of knowledge inputs and innovation value: The moderating effect of firm age and size. Journal of Business Research, No. 86, pp. 190—201. https://doi.org/10.1016/j.jbusres.2018.02.009Dickinson V. (2011). Cash flow patterns as a proxy for firm life-cycle. Accounting Review, Vol. 86, No. 6, pp. 1969—1994. https://doi.org/10.2308/accr-10130Dickinson V. (2011). Cash flow patterns as a proxy for firm life-cycle. Accounting Review, Vol. 86, No. 6, pp. 1969—1994. https://doi.org/10.2308/accr-10130Dierickx I., Cool K. (1989). Asset stock accumulation and sustainability of competitive advantage. Management Science, Vol. 35, No. 12, pp. 1504—1511. https://doi.org/10.1287/mnsc.35.12.1504Dierickx I., Cool K. (1989). Asset stock accumulation and sustainability of competitive advantage. Management Science, Vol. 35, No. 12, pp. 1504—1511. https://doi.org/10.1287/mnsc.35.12.1504Ding M., Eliashberg J., Stremersch S. (2014). Innovation and marketing in the pharmaceutical industry. Emerging Practices, Research, and Policies. New York: Springer. https://doi.org/10.1007/978-1-4614-7801-0Ding M., Eliashberg J., Stremersch S. (2014). Innovation and marketing in the pharmaceutical industry. Emerging Practices, Research, and Policies. New York: Springer. https://doi.org/10.1007/978-1-4614-7801-0Ettlie J. E., Rubenstein A. H. (1987). Firm size and product innovation. Journal of Product Innovation Management, Vol. 4, No. 2, pp. 89—108. https://doi.org/10.1016/0737-6782(87)90055-5Ettlie J. E., Rubenstein A. H. (1987). Firm size and product innovation. Journal of Product Innovation Management, Vol. 4, No. 2, pp. 89—108. https://doi.org/10.1016/0737-6782(87)90055-5Evaluate Pharma (2020). World preview 2020, outlook to 2026.Evaluate Pharma (2020). World preview 2020, outlook to 2026.Fishburn C. S. (2015). Translational medicine: The changing role of big pharma. In: M. Wehling (ed.). Principles of translational science in medicine: From bench to bedside, 2nd ed. Elsevier, pp. 313—325. https://doi.org/10.1016/b978-0-12-800687-0.00032-3Fishburn C. S. (2015). Translational medicine: The changing role of big pharma. In: M. Wehling (ed.). Principles of translational science in medicine: From bench to bedside, 2nd ed. Elsevier, pp. 313—325. https://doi.org/10.1016/b978-0-12-800687-0.00032-3Forsman H. (2011). Innovation capacity and innovation development in small enterprises. A comparison between the manufacturing and service sectors. Research Policy, Vol. 40, No. 5, pp. 730—750. https://doi.org/10.1016/j.respol.2011.02.003Forsman H. (2011). Innovation capacity and innovation development in small enterprises. A comparison between the manufacturing and service sectors. Research Policy, Vol. 40, No. 5, pp. 730—750. https://doi.org/10.1016/j.respol.2011.02.003Hilmersson F. P., Hilmersson M. (2020). Networking to accelerate the pace of SME innovations. Journal of Innovation & Knowledge, Vol. 6, No. 1, pp. 43—49. https:// doi.org/10.1016/j.jik.2020.10.001Hilmersson F. P., Hilmersson M. (2020). Networking to accelerate the pace of SME innovations. Journal of Innovation & Knowledge, Vol. 6, No. 1, pp. 43—49. https:// doi.org/10.1016/j.jik.2020.10.001Huergo E., Jaumandreu J. (2004). Firms’ age, process innovation and productivity growth. International Journal of Industrial Organization, Vol. 22, No. 4, pp. 541—559. https://doi.org/10.1016/j.ijindorg.2003.12.002Huergo E., Jaumandreu J. (2004). Firms’ age, process innovation and productivity growth. International Journal of Industrial Organization, Vol. 22, No. 4, pp. 541—559. https://doi.org/10.1016/j.ijindorg.2003.12.002Kiriri P. N. (2004). Small and medium enterprises (SMEs): Validating life cycle stage determinants. Australian Journal of Business and Social Inquiry, Vol. 2, No. 1.Kiriri P. N. (2004). Small and medium enterprises (SMEs): Validating life cycle stage determinants. Australian Journal of Business and Social Inquiry, Vol. 2, No. 1.Kurji N. (2019). The future of pharma: The role of biotech companies. Forbes, May 29. https://www.forbes.com/sites/forbestechcouncil/2019/05/29/the-future-ofpharma-the-role-of-biotech-companies/?sh=6e505fc76bb3Kurji N. (2019). The future of pharma: The role of biotech companies. Forbes, May 29. https://www.forbes.com/sites/forbestechcouncil/2019/05/29/the-future-ofpharma-the-role-of-biotech-companies/?sh=6e505fc76bb3Lopes C. M., Scavarda A., Hofmeister L. F., Thomé A. M. T., Vaccaro G. L. R. (2016). An analysis of the interplay between organizational sustainability, knowledge management, and open innovation. Journal of Cleaner Production, Vol. 142, pp. 476—488. https://doi.org/10.1016/j.jclepro.2016.10.083Lopes C. M., Scavarda A., Hofmeister L. F., Thomé A. M. T., Vaccaro G. L. R. (2016). An analysis of the interplay between organizational sustainability, knowledge management, and open innovation. Journal of Cleaner Production, Vol. 142, pp. 476—488. https://doi.org/10.1016/j.jclepro.2016.10.083Mark A. (2018). The role of big pharma. The Hawk Newspaper. Special Issue: Opioid, April 18. http://www.sjuhawknews.com/the-role-of-big-pharmaMark A. (2018). The role of big pharma. The Hawk Newspaper. Special Issue: Opioid, April 18. http://www.sjuhawknews.com/the-role-of-big-pharmaMazzarol T., Reboud S., Volery T. (2010). The influence of size, age and growth on innovation management in small firms. International Journal of Sustainable Agricultural Management and Informatics, Vol. 52, No. 1/2, pp. 98—117. https://doi.org/10.1504/IJTM.2010.035857Mazzarol T., Reboud S., Volery T. (2010). The influence of size, age and growth on innovation management in small firms. International Journal of Sustainable Agricultural Management and Informatics, Vol. 52, No. 1/2, pp. 98—117. https://doi.org/10.1504/IJTM.2010.035857Miller D., Friesen P. H. (1984). A longitudinal study of the corporate life cycle. Management Science, Vol. 30, No. 10, pp. 1161—1183. https://doi.org/10.1287/mnsc.30.10.1161Miller D., Friesen P. H. (1984). A longitudinal study of the corporate life cycle. Management Science, Vol. 30, No. 10, pp. 1161—1183. https://doi.org/10.1287/mnsc.30.10.1161Morck R., Yeung B. (2001). The economic determinants of innovation. Industry Canada Occasional Paper, No. 25.Morck R., Yeung B. (2001). The economic determinants of innovation. Industry Canada Occasional Paper, No. 25.Muda S., Rahman M. R. C. A. (2016). Human сapital in SMEs life cycle perspective. Procedia Economics and Finance, Vol. 35, pp. 683—689. https://doi.org/10.1016/S2212-5671(16)00084-8Muda S., Rahman M. R. C. A. (2016). Human сapital in SMEs life cycle perspective. Procedia Economics and Finance, Vol. 35, pp. 683—689. https://doi.org/10.1016/S2212-5671(16)00084-8Murphey R. (2020). A framework for comparing R&D productivity at big pharma companies vs. biotech startups. Journal of Commercial Biotechnology, Vol. 25, Vol. 4. https://doi.org/10.5912/jcb951Murphey R. (2020). A framework for comparing R&D productivity at big pharma companies vs. biotech startups. Journal of Commercial Biotechnology, Vol. 25, Vol. 4. https://doi.org/10.5912/jcb951National Science Board (2012). Science and engineering indicators 2012. Arlington, VA: National Science Foundation.National Science Board (2012). Science and engineering indicators 2012. Arlington, VA: National Science Foundation.Nieminen J. (2019). Innovation maturity matrix — A model to successful innovation transformation. Viima.com, November 1. https://www.viima.com/blog/innovation-maturity-matrixNieminen J. (2019). Innovation maturity matrix — A model to successful innovation transformation. Viima.com, November 1. https://www.viima.com/blog/innovation-maturity-matrixOECD, Eurostat (2018). Oslo manual 2018: Guidelines for collecting, reporting and using data on innovation. Luxembourg: OECD Publishing.OECD, Eurostat (2018). Oslo manual 2018: Guidelines for collecting, reporting and using data on innovation. Luxembourg: OECD Publishing.Robinson R. (2020). Small pharma driving big pharma innovation. PharmaVOICE, January. https://www.pharmavoice.com/article/2020-01-pharma-innovationRobinson R. (2020). Small pharma driving big pharma innovation. PharmaVOICE, January. https://www.pharmavoice.com/article/2020-01-pharma-innovationSzetto E. (2001). Innovation сapacity: Working toward a mechanism for improving innovation within an inter-organizational network. The TQM Magazine, Vol. 12, No. 2, pp. 149—152. https://doi.org/10.1108/09544780010318415Szetto E. (2001). Innovation сapacity: Working toward a mechanism for improving innovation within an inter-organizational network. The TQM Magazine, Vol. 12, No. 2, pp. 149—152. https://doi.org/10.1108/09544780010318415Yoo J., Lee S., Park S. (2019). The effect of firm life cycle on the relationship between R&D expenditures and future performance, earnings uncertainty, and sustainable growth. Sustainability, Vol. 11, No. 8, article 2371. https://doi.org/10.3390/su11082371Yoo J., Lee S., Park S. (2019). The effect of firm life cycle on the relationship between R&D expenditures and future performance, earnings uncertainty, and sustainable growth. Sustainability, Vol. 11, No. 8, article 2371. https://doi.org/10.3390/su11082371

The authors declare that there are no conflicts of interest present.